Raising the bar: The curative potential of human cancer immunotherapy

Steven A. Rosenberg

Research output: Contribution to journalReview article

Abstract

Immunotherapy with interleukin-2 can cure 5 to 10% of patients with metastatic melanoma and renal cancer. Recent adoptive cell transfer (ACT) immunotherapies have improved cure rates in metastatic melanoma to 20 to 40%. Genetic engineering of T cells to express conventional alpha/beta T cell receptors or antibody-based chimeric antigen receptors provides an opportunity to extend ACT to patients with common epithelial cancers.

Original languageEnglish (US)
Article number127ps8
JournalScience translational medicine
Volume4
Issue number127
DOIs
StatePublished - Mar 28 2012

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this